Back
Bio-Rad Laboratories, Inc. (BIO)
Life Sciences Tools & ServicesBIO · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$366.16
+1.60%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$27.85
ROE
2.5%
Gross margin
52.0%
Debt/Equity
0.20x
Revenue growth
1.1%
Bio-Rad Laboratories, Inc. — company intelligence
Earnings surprises
Q2 2026$2.62 vs $1.77 est+48.4%
Q1 2026$1.89 vs $2.00 est-5.7%
Q4 2025$2.51 vs $2.73 est-8.0%
Q3 2025$2.26 vs $1.95 est+15.7%
Analyst consensus · 10 analysts
5 Buy4 Hold1 Sell
Updated Oct 9, 2026
Recent SEC filings
4 — Insider transaction reportSep 9, 2026
4 — Insider transaction reportSep 9, 2026
4 — Insider transaction reportSep 9, 2026
Latest news
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum — Yahoo · 3w ago
Bio-Rad: Favorable Read-Across From Investor Event — SeekingAlpha · Sep 10, 2026
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript — SeekingAlpha · Sep 9, 2026
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? — Yahoo · Sep 3, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.